SOMATULINE (BIM-23014) AND TAMOXIFEN TREATMENT OF POSTMENOPAUSAL BREAST-CANCER PATIENTS - CLINICAL ACTIVITY AND EFFECT ON INSULIN-LIKE-GROWTH-FACTOR-I (IGF-I) LEVELS

Somatostatin analogues have been shown to suppress some hormones and g rowth factors involved in breast tumour growth and a direct in vivo an d clinical antimumour effect has recently been reported. In our study the effects of tamoxifen, combined with a depot somatostatin analogue in 33 postmenopausal untreated breast cancer patients, have been evalu ated. Blood samples were obtained before treatment, after 14 days and then monthly, in order to evaluate the behaviour of serum IGF-I, GH an d somatuline levels. The drug combination resulted in a significant an d synergistic reduction of plasma IGF-I concentration. No significant changes of serum GH were observed 12.5% of patients exhibited a comple te response and 37.5% a partial response for an overall objective resp onse rate of 50% (95% CL 35-69%). The high remission rate reported the absence of overlapping side effects between tamoxifen and somatuline and the synergistic activity on IGF-I suppression justify a further ev aluation of the drug-combination.